Literature DB >> 18241159

An alternative approach to projecting health expenditure in Australia.

Stephen Begg1, Theo Vos, John Goss, Nicholas Mann.   

Abstract

OBJECTIVE: To introduce a large body of work that explores the modelling of expenditure on health services per person living with major causes of disease or injury as a valid basis for conclusions regarding future health expenditure in Australia.
METHODS: Separate projections were calculated for important health conditions (or groups of conditions) by type of expenditure (hospital care, medical services, pharmaceuticals, aged care homes and other health services). Analyses accounted for expected changes in the number of affected cases, the proportion of cases treated, the volume of health services per treated case and excess health price inflation.
RESULTS: Total health expenditure in Australia is expected to increase from 9.4% of GDP in 2002-03 to 10.8% of GDP in 2032-33. This represents a 15% increase in the "health : GDP" proportion over the projection period, or an annual growth of 0.5%. Two-thirds of this growth is accounted for by expected increases in population size and population ageing.
CONCLUSIONS: The lower annual growth in the "health : GDP" proportion compared with other estimates for Australia (range, 0.9% to 1.7%) was attributed to different assumptions regarding non-demographic growth factors, particularly volume per case. Explicit modelling of these factors separately for each condition ensured that assumptions remained within plausible limits.

Entities:  

Mesh:

Year:  2008        PMID: 18241159     DOI: 10.1071/ah080148

Source DB:  PubMed          Journal:  Aust Health Rev        ISSN: 0156-5788            Impact factor:   1.990


  8 in total

1.  Assessing the cost-effectiveness of drug and lifestyle intervention following opportunistic screening for pre-diabetes in primary care.

Authors:  M Y Bertram; S S Lim; J J Barendregt; T Vos
Journal:  Diabetologia       Date:  2010-02-05       Impact factor: 10.122

Review 2.  Health Expenditure Data, Analysis and Policy Relevance in Australia, 1967 to 2020.

Authors:  John R Goss
Journal:  Int J Environ Res Public Health       Date:  2022-02-14       Impact factor: 3.390

3.  Global, regional, and national disability-adjusted life-years (DALYs) for 359 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.

Authors: 
Journal:  Lancet       Date:  2018-11-10       Impact factor: 79.321

4.  Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.

Authors: 
Journal:  Lancet       Date:  2016-10-08       Impact factor: 79.321

5.  Improving the cost-effectiveness of cardiovascular disease prevention in Australia: a modelling study.

Authors:  Linda J Cobiac; Anne Magnus; Jan J Barendregt; Rob Carter; Theo Vos
Journal:  BMC Public Health       Date:  2012-06-01       Impact factor: 3.295

6.  Forecasting the burden of type 2 diabetes in Singapore using a demographic epidemiological model of Singapore.

Authors:  Thao P Phan; Leontine Alkema; E Shyong Tai; Kristin H X Tan; Qian Yang; Wei-Yen Lim; Yik Ying Teo; Ching-Yu Cheng; Xu Wang; Tien Yin Wong; Kee Seng Chia; Alex R Cook
Journal:  BMJ Open Diabetes Res Care       Date:  2014-06-11

7.  Which interventions offer best value for money in primary prevention of cardiovascular disease?

Authors:  Linda J Cobiac; Anne Magnus; Stephen Lim; Jan J Barendregt; Rob Carter; Theo Vos
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

8.  Adjusting health spending for the presence of comorbidities: an application to United States national inpatient data.

Authors:  Joseph L Dieleman; Ranju Baral; Elizabeth Johnson; Anne Bulchis; Maxwell Birger; Anthony L Bui; Madeline Campbell; Abigail Chapin; Rose Gabert; Hannah Hamavid; Cody Horst; Jonathan Joseph; Liya Lomsadze; Ellen Squires; Martin Tobias
Journal:  Health Econ Rev       Date:  2017-08-29
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.